Inhibition of Polyglutamine Aggregation in R6/2 HD Brain Slices—Complex Dose–Response Profiles
Huntington's disease (HD) is a late onset neurodegenerative disorder caused by a CAG/polyglutamine (polyQ) repeat expansion. PolyQ aggregates can be detected in the nuclei and processes of neurons in HD patients and mouse models prior to the onset of symptoms. The misfolding and aggregation pat...
Main Authors: | Donna L. Smith, Ruben Portier, Ben Woodman, Emma Hockly, Amarbirpal Mahal, William E. Klunk, Xiao-Jiang Li, Erich Wanker, Karl D. Murray, Gillian P. Bates |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2001-12-01
|
Series: | Neurobiology of Disease |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996101904383 |
Similar Items
-
Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3
by: Li Zeng, et al.
Published: (2015-10-01) -
Molecular origin of polyglutamine aggregation in neurodegenerative diseases.
by: Sagar D Khare, et al.
Published: (2005-08-01) -
Molecular origin of polyglutamine aggregation in neurodegenerative diseases.
Published: (2005-08-01) -
Candida albicans Is Resistant to Polyglutamine Aggregation and Toxicity
by: Michelle D. Leach, et al.
Published: (2017-01-01) -
Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease
by: Emma Hockly, et al.
Published: (2006-01-01)